VEGFA and neoplasm: Over the past decade, recognition that von Hippel-Lindau (VHL) gene mutations cause overexpression of vascular endothelial growth factor (VEGF) and increased tumor angiogenesis has led to development of multiple agents targeting this protein and its receptor.